{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:42:05Z","timestamp":1773232925478,"version":"3.50.1"},"reference-count":61,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Resistance to immune checkpoint inhibitors (ICIs) reduces treatment efficacy in 40\u201365% of patients. The ability to predict this at the outset of therapy could help optimise treatment selection and improve patient survival. The aim of this study was to identify factors associated with primary resistance to PD-1 inhibitors in metastatic melanoma and discover predictive markers. Materials and Methods: This retrospective study involved 110 patients with non-uveal metastatic melanoma treated with PD-1 inhibitors from 2016 to 2023. Demographic, clinical and haematological data were collected. LASSO regression was utilised to identify the best markers. Bootstrap resampling was performed for internal validation and to overcome overfitting. Results: Primary resistance occurred in 44.6% of the patients. The factors associated with resistance included elevated platelet-to-lymphocyte ratio (PLR), the presence of acral\/mucosal melanoma, BRAF mutant disease, low globulin levels and \u22653 metastatic sites. An evaluation of the predictive capability of these variables showed robust discrimination, with an area under the receiver operating characteristic curve of 0.831. Conclusions: This study identified the key predictors of primary resistance to PD-1 inhibitors to be PLR, globulin levels, metastatic burden and melanoma subtype. These identified parameters may guide the early prediction of primary resistance to PD-1 inhibitors. Future work should externally validate the model and further explore robust strategies to overcome resistance.<\/jats:p>","DOI":"10.3390\/medicina61091559","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T16:18:15Z","timestamp":1756484295000},"page":"1559","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["LASSO-Driven Selection of Biochemical and Clinical Markers for Primary Resistance to PD-1 Inhibitors in Metastatic Melanoma"],"prefix":"10.3390","volume":"61","author":[{"given":"Haydar C.","family":"Yuksel","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Ege University Medical Faculty, Izmir 35100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-6807","authenticated-orcid":false,"given":"Caner","family":"Acar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ege University Medical Faculty, Izmir 35100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-9383","authenticated-orcid":false,"given":"Gokhan","family":"Sahin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ege University Medical Faculty, Izmir 35100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulcin","family":"Celebi","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Ege University Medical Faculty, Izmir 35100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salih","family":"Tunbekici","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Ege University Medical Faculty, Izmir 35100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burcak S.","family":"Karaca","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ege University Medical Faculty, Izmir 35100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: Three-year follow-up of a randomized phase 3 trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1158\/1078-0432.CCR-20-0177","article-title":"Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B","volume":"26","author":"Carlino","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.22.02199","article-title":"First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401","volume":"41","author":"Dummer","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1200\/JCO.21.01701","article-title":"Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma","volume":"40","author":"Ahmed","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.3390\/curroncol31100472","article-title":"Exploring the Frequency and Risk Factors of Hyperprogressive Disease in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors","volume":"31","author":"Acar","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zhang, C., Zhang, C., and Wang, H. (2023). Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions. Cancer Lett., 562.","DOI":"10.1016\/j.canlet.2023.216182"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Amaral, T., Seeber, O., Mersi, E., Sanchez, S., Thomas, I., Meiwes, A., Forschner, A., Leiter, U., Eigentler, T.K., and Keim, U. (2020). Primary Resistance to PD-1-Based Immunotherapy\u2014A Study in 319 Patients with Stage IV Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12041027"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kluger, H., Barrett, J.C., Gainor, J.F., Hamid, O., Hurwitz, M., LaVallee, T., Moss, R.A., Zappasodi, R., Sullivan, R.J., and Tawbi, H. (2023). Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. J. Immunother. Cancer, 11.","DOI":"10.1136\/jitc-2022-005921"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ziogas, D.C., Theocharopoulos, C., Koutouratsas, T., Haanen, J., and Gogas, H. (2023). Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?. Cancer Treat. Rev., 113.","DOI":"10.1016\/j.ctrv.2022.102499"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Slominski, R.M., Sarna, T., P\u0142onka, P.M., Raman, C., Bro\u017cyna, A.A., and Slominski, A.T. (2022). Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.842496"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Slominski, R.M., Kim, T.-K., Janjetovic, Z., Bro\u017cyna, A.A., Podgorska, E., Dixon, K.M., Mason, R.S., Tuckey, R.C., Sharma, R., and Crossman, D.K. (2024). Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling. Cancers, 16.","DOI":"10.3390\/cancers16122262"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tins.2023.01.003","article-title":"How cancer hijacks the body\u2019s homeostasis through the neuroendocrine system","volume":"46","author":"Slominski","year":"2023","journal-title":"Trends Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Byeon, S., Cho, H.J., Jang, K.T., Kwon, M., Lee, J., Lee, J., and Kim, S.T. (2021). Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. ESMO Open, 6.","DOI":"10.1016\/j.esmoop.2020.100002"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"van Not, O.J., Blokx, W.A.M., van den Eertwegh, A.J.M., de Meza, M.M., Haanen, J.B., Blank, C.U., Aarts, M.J.B., van den Berkmortel, F.W.P.J., de Groot, J.W.B., and Hospers, G.A.P. (2022). BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma. JCO Precis. Oncol., 6.","DOI":"10.1200\/PO.22.00018"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Borch, T.H., Harbst, K., Rana, A.H., Andersen, R., Martinenaite, E., Kongsted, P., Pedersen, M., Nielsen, M., Kjeldsen, J.W., and Kverneland, A.H. (2021). Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. J. Immunother. Cancer, 9.","DOI":"10.1136\/jitc-2021-002703"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, W., Kong, Y., Li, Y., Shi, F., Lyu, J., Sheng, C., Wang, S., and Wang, Q. (2022). Novel molecular determinants of response or resistance to immune checkpoint inhibitor therapies in melanoma. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.798474"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hossain, S.M., Gimenez, G., Stockwell, P.A., Tsai, P., Print, C.G., Rys, J., Cybulska-Stopa, B., Ratajska, M., Harazin-Lechowska, A., and Almomani, S. (2022). Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.955063"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: Triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-21-0888","article-title":"Early tumor\u2013immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ou, Y., Liang, S., Gao, Q., Shang, Y., Liang, J., Zhang, W., and Liu, S. (2024). Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: A meta-analysis and systematic review. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1482746"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Acar, C., Y\u00fcksel, H.\u00c7., \u015eahin, G., A\u00e7ar, F.P., Gunenc, D., and Karaca, B. (2025). Prognostic utility of the CALLY index in metastatic melanoma: Building a nomogram for Patients on Anti-PD-1 therapy. Clin. Transl. Oncol.","DOI":"10.1007\/s12094-025-03888-z"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Paolino, G., Huber, V., Camerini, S., Casella, M., Macone, A., Bertuccini, L., Iosi, F., Moliterni, E., Cecchetti, S., and Ruspantini, I. (2021). The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients. Cancers, 13.","DOI":"10.20944\/preprints202105.0577.v1"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lauss, M., Phung, B., Borch, T.H., Harbst, K., Kaminska, K., Ebbesson, A., Hedenfalk, I., Yuan, J., Nielsen, K., and Ingvar, C. (2024). Molecular patterns of resistance to immune checkpoint blockade in melanoma. Nat. Commun., 15.","DOI":"10.1038\/s41467-024-47425-y"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tao, W., Sun, Q., Xu, B., and Wang, R. (2025). Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review. Life, 15.","DOI":"10.3390\/life15020283"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zhao, S., Li, Z., Liu, K., Wang, G., Wang, Q., Yu, H., Chen, W., Dai, H., Li, Y., and Xie, J. (2025). Combining multi-omics analysis with machine learning to uncover novel molecular subtypes, prognostic markers, and insights into immunotherapy for melanoma. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14012-3"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gschwind, A., and Ossowski, S. (2025). AI Model for Predicting Anti-PD1 Response in Melanoma Using Multi-Omics Biomarkers. Cancers, 17.","DOI":"10.20944\/preprints202501.0904.v1"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/ijc.34853","article-title":"A prediction model for response to immune checkpoint inhibition in advanced melanoma","volume":"154","author":"Verheijden","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bjc.2017.70","article-title":"Evaluation of clinicopathological factors in PD-1 response: Derivation and validation of a prediction scale for response to PD-1 monotherapy","volume":"116","author":"Nosrati","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Birnboim-Perach, R., and Benhar, I. (2024). Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment. Int. J. Biol. Sci., 20.","DOI":"10.7150\/ijbs.93697"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Pavlick, A.C., Ariyan, C.E., Buchbinder, E.I., Davar, D., Gibney, G.T., Hamid, O., Hieken, T.J., Izar, B., Johnson, D.B., and Kulkarni, R.P. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. J. Immunother. Cancer, 11.","DOI":"10.1136\/jitc-2023-006947"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Atkins, M.B., Lee, S.J., Chmielowski, B., Ribas, A., Tarhini, A.A., Truong, T.-G., Davar, D., O\u2019Rourke, M.A., Curti, B.D., and Brell, J.M. (2021). DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): A phase III trial\u2014ECOG-ACRIN EA6134. J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.2021.39.36_suppl.356154"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1158\/1535-7163.MCT-14-0290","article-title":"Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma","volume":"13","author":"Ilieva","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s43018-021-00221-9","article-title":"Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma","volume":"2","author":"Haas","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2478\/raon-2020-0003","article-title":"Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab\u2013real-world experience","volume":"54","author":"Hribernik","year":"2020","journal-title":"Radiol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-2051-8","article-title":"Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy","volume":"17","author":"Seremet","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/CJI.0000000000000186","article-title":"Efficacy and safety of pembrolizumab in patients enrolled in KEYNOTE-030 in the United States: An expanded access program","volume":"40","author":"Gangadhar","year":"2017","journal-title":"J. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2019.05.015","article-title":"Efficacy of PD-1\u2013based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma","volume":"116","author":"Kreft","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Guven, D.C., Sahin, T.K., Erul, E., Rizzo, A., Ricci, A.D., Aksoy, S., and Yalcin, S. (2022). The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.1039121"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s10147-019-01539-2","article-title":"Albumin\u2013globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer","volume":"25","author":"Nakanishi","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1080\/01635581.2022.2032764","article-title":"The prognostic value of albumin-globulin ratio and eosinophil-neutrophil ratio in patients with advanced tumors undergoing treatment with PD-1\/PD-L1 inhibitors","volume":"74","author":"Ma","year":"2022","journal-title":"Nutr. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Shebrain, A., Idris, O.A., Jawad, A., Zhang, T., and Xing, Y. (2024). Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13185409"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Wang, R., Chen, Y., Xie, Y., Ma, X., and Liu, Y. (2024). Deciphering and overcoming Anti-PD-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies. Int. Immunopharmacol., 132.","DOI":"10.1016\/j.intimp.2024.111989"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2147\/OTT.S159481","article-title":"Albumin\/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients","volume":"11","author":"Liu","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/CJI.0000000000000255","article-title":"Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment","volume":"42","author":"Diem","year":"2019","journal-title":"J. Immunother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti\u2013PD-1 therapy","volume":"126","author":"Lo","year":"2020","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/pcmr.12675","article-title":"Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma","volume":"31","author":"Lee","year":"2018","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_50","unstructured":"Seeber, T.O. (2021). Primary Resistance to Immune Checkpoint Inhibitors in Patients with Metastatic Melanoma: Prognosis, Subsequent Therapies and Survival. [Ph.D. Thesis, Universit\u00e4t T\u00fcbingen]."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Champiat, S., Matte, P., Baldini, C., Vasseur, D., Ouali, K., Gazzah, A., Bahleda, R., Bayle, A., Postel-Vinay, S., and Smolenschi, C. (2023). Abstract C068: Factors associated with primary resistance to immune checkpoint blockade in early phase clinical trials. Mol. Cancer Ther., 22.","DOI":"10.1158\/1535-7163.TARG-23-C068"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Maugeais, M., Peron, J., Dalle, S., Duruisseaux, M., Corbaux, P., Reverdy, T., Lopez, J., Souquet, P.J., and Maillet, D. (2020). 1038P Impact of metastatic location on immune-checkpoint inhibitors efficacy in patients with different solid tumours. Ann. Oncol., 31.","DOI":"10.1016\/j.annonc.2020.08.1158"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/cmi.2015.112","article-title":"Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells","volume":"13","author":"Horst","year":"2016","journal-title":"Cell Mol. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Shui, I.M., Liu, X.Q., Zhao, Q., Kim, S.T., Sun, Y., Yearley, J.H., Choudhury, T., Webber, A.L., Krepler, C., and Cristescu, R. (2022). Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: An observational study. J. Immunother. Cancer, 10.","DOI":"10.1136\/jitc-2022-004879"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Gui, J., Guo, Z., and Wu, D. (2022). Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma. J. Transl. Med., 20.","DOI":"10.1186\/s12967-022-03532-2"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Huang, Y., Zhao, J.J., Soon, Y.Y., Kee, A., Tay, S.H., Aminkeng, F., Ang, Y., Wong, A.S.C., Bharwani, L.D., and Goh, B.C. (2023). Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Cancers, 15.","DOI":"10.3390\/cancers15102733"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Splendiani, E., Besharat, Z.M., Covre, A., Maio, M., Di Giacomo, A.M., and Ferretti, E. (2024). Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?. Pharmacol. Ther., 256.","DOI":"10.1016\/j.pharmthera.2024.108613"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Li, J., Liu, J., Yang, S., Xia, Y., Meng, Q., Sun, B., Liu, Y., Zhao, B., Jin, J., and Xu, H. (2025). PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer. Cell Commun. Signal, 23.","DOI":"10.1186\/s12964-025-02034-0"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Young, R., Panchal, H., Ma, W., Chen, S., Steele, A.P., Iannucci, A.A., and Li, T. (2022). Low lymphocyte counts and association with clinical outcomes in hospitalized patients with cancer receiving immune checkpoint inhibitor therapy. J. Clin. Oncol., 40.","DOI":"10.1200\/JCO.2022.40.16_suppl.e14600"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"M\u00e9n\u00e9trier-Caux, C., Ray-Coquard, I., Blay, J.-Y., and Caux, C. (2019). Lymphopenia in cancer patients and its effects on response to immunotherapy: An opportunity for combination with cytokines?. J. Immunother. Cancer, 7.","DOI":"10.1186\/s40425-019-0549-5"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/CMR.0000000000000850","article-title":"Resistance to anti-PD1 therapies in patients with advanced melanoma: Systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions","volume":"32","author":"Shui","year":"2022","journal-title":"Melanoma Res."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1559\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:35:39Z","timestamp":1760034939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medicina61091559"],"URL":"https:\/\/doi.org\/10.3390\/medicina61091559","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}